引用本文:候传星,黄绍湘,陶志悦.胺碘酮与维拉帕米静脉注射治疗阵发性室上性心动过速疗效对比的Meta分析[J].中国临床新医学,2017,10(4):325-329.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 1876次   下载 1371 本文二维码信息
码上扫一扫!
分享到: 微信 更多
胺碘酮与维拉帕米静脉注射治疗阵发性室上性心动过速疗效对比的Meta分析
候传星,黄绍湘,陶志悦
530001 南宁,广西中医药大学(候传星,陶志悦);530011 南宁,广西中医药大学附属瑞康医院急诊科(黄绍湘)
摘要:
[摘要] 目的 比较静脉注射胺碘酮与维拉帕米在治疗阵发性室上性心动过速疗效、安全性及复律时间上的差异。方法 收集2005-01~2015-12公开发表的有关两种药物在治疗阵发性室上性心动过速的中文和英文文献,按标准严格筛选后,评估文献质量并提取完整数据资料,最后应用RevMan 5.20软件进行系统分析评价。结果 最终纳入随机对照试验资料10篇,Meta分析结果显示,静脉注射胺碘酮组与维拉帕米组相比在治疗阵发性室上性心动过速疗效上差异无统计学意义(OR=0.73,95%CI=0.35~1.53,P=0.41);胺碘酮组不良反应发生率低于维拉帕米组,差异有统计学意义(OR=0.34,95%CI=0.21~0.57,P<0.01);两药治疗阵发性室上性心动过速在复律时间上,维拉帕米优于胺碘酮,差异有统计学意义(OR=7.90,95%CI=3.35~12.44,P<0.01)。结论 与维拉帕米相比,胺碘酮在治疗阵发性室上性心动过速上具有更好的安全性、可靠性,但复律时间慢于维拉帕米。
关键词:  胺碘酮  维拉帕米  阵发性室上性心动过速  Meta分析
DOI:10.3969/j.issn.1674-3806.2017.04.09
分类号:R 541.7
基金项目:
Curative effect of intravenous injections of amiodarone and verapamil on paroxysmal supraventricular tachycardia:a Meta-analysis
HOU Chuan-xing, HUANG Shao-xiang, TAO Zhi-yue
Guangxi University of Chinese Medicine, Nanning 530001, China
Abstract:
[Abstract] Objective To evaluate the clinical effects of intravenous injections of amiodarone and verapamil on the treatment of paroxysmal supraventricular tachycardia(PSVT).Methods Medical articles of randomized controlled trials published in Chinese and English about the treatment of PSVT were searched in the Cochrane library and on the databases of PubMed, EMBASE, CNKI, VIP and Wangfang from January 2005 to December 2015, with a strictly screening according to the standard of assessing the quality of the literatures. The data of the selective trials were analyzed by the RevMan 5.20 software.Results A total of ten randomized clinical trials were included. The Meta-analysis showed that there was no significant difference between the amiodarone group and the verapamil group in the curative effect of PSVT(OR=0.73,95%CI=0.35~1.53,P=0.41); The incidence of adverse reactions of the amiodarone group was significantly lower than that of the verapamil group(OR=0.34, 95%CI=0.21~0.57, P<0.01); The cardioversion time of PSVT in the verapamil group was significantly shorter than that in the amiodarone group(OR=7.90, 95%CI=3.35~12.44, P<0.01).Conclusion Amiodarone is more safe and reliable than verapamil in the treatment of PSVT. The cardioversion time of amiodarone is longer than that of verapamil.
Key words:  Amiodarone  Verapamil  Paroxysmal supraventricular tachycardia(PSVT)  Meta-analysis